World News: 14:10 GMT Thursday 29th August 2019. [CytoDyn Inc. via Globe Newswire via SPi World News]
VANCOUVER Washington Aug 29 2019 GLOBE NEWSWIRE -- LINK or the Company a late stage biotechnology company developing leronlimab PRO 140 a CCR5 antagonist with the LINK for multiple therapeutic indications announc ed toda...
More news and information about CytoDyn Inc.
Globe Newswire: 14:10 GMT Thursday 29th August 2019
Published: 2019-08-29T14:10:00.
Search for other references to "cytodyn" on SPi News
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us